Stock CALT CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Market Closed - Nasdaq
Other stock markets
 21:30:01 10/06/2024 BST 		5-day change 1st Jan Change
39.5 USD +0.03% Intraday chart for Calliditas Therapeutics AB +0.38% +53.43%
06-07 European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
06-06 Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
AQ
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
BU
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
AQ
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
AQ
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)
PU
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Report)
PU
Calliditas Q1 report, January - March 2024
AQ
In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024
PU
Invitation to the presentation of Calliditas's interim report January - March 2024
AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
AQ
Calliditas Therapeutics' 2023 Annual Report Published
AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results
AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
AQ
Calliditas Therapeutics to Attend Conferences in April
AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. CALT Stock
  5. News Calliditas Therapeutics AB
  6. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW